Document and Entity Information
Document and Entity Information | Dec. 14, 2022 |
Cover [Abstract] | |
Security Exchange Name | NASDAQ |
Amendment Flag | true |
Entity Central Index Key | 0001445283 |
Document Type | 8-K/A |
Document Period End Date | Dec. 14, 2022 |
Entity Registrant Name | YUMANITY THERAPEUTICS, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-37695 |
Entity Tax Identification Number | 20-8436652 |
Entity Address, Address Line One | 40 Guest Street |
Entity Address, Address Line Two | Suite 4410 |
Entity Address, City or Town | Boston |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02135 |
City Area Code | 617 |
Local Phone Number | 409-5300 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.001 per share |
Trading Symbol | YMTX |
Entity Emerging Growth Company | false |
Amendment Description | This Current Report on Form 8-K/A (this “Amendment”) amends the Current Report on Form 8-K of Yumanity Therapeutics, Inc. (“Yumanity”) filed with the U.S. Securities and Exchange Commission on December 15, 2022 (the “Original Form 8-K”). The Original Form 8-K reported that the ex-dividend date for payment of the special cash dividend payable to stockholders of record as of the close of business on December 15, 2022 (the “Special Dividend”), will be December 16, 2022. The sole purpose of this Amendment is to disclose that the Nasdaq Capital Market (“Nasdaq”) has informed the Company that the ex-dividend date of the Special Dividend will be December 19, 2022 as further described below. |